Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA7 | P43166 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SELL | P14151 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SELP | P16109 | 1/20 | 0.48 |
| ▸ | FUT4 | P22083 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26121716 | 0.87 | KDM4E (0.58) | TTRLMNACA12CA1CA2 | |
| SCHEMBL31297436 | 0.85 | TPMT (0.54) | TTRLMNACA12CA1CA2 | |
| SCHEMBL31700656 | 0.85 | TPMT (0.45) | TTRLMNACA12CA1CA2 | |
| SCHEMBL31174965 | 0.85 | TTR (0.52) | TTRLMNACA12CA1CA2 | |
| SCHEMBL31049112 | 0.85 | TTR (0.52) | TTRLMNACA12CA1CA2 | |
| SCHEMBL22569479 | 0.80 | ALDH1A1 (0.46) | TTRLMNACA12CA1CA2 | |
| SCHEMBL18340205 | 0.80 | HTT (0.59) | TTRLMNACA12CA1CA2 | |
| SCHEMBL1724284 | 0.79 | TTR (0.56) | TTRLMNACA12CA1CA2 | |
| SCHEMBL30753326 | 0.79 | TTR (0.56) | TTRLMNACA12CA1CA2 | |
| SCHEMBL221480 | 0.79 | CES2 (0.67) | TTRLMNACA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108947782-B | Bromofluoride multi-substituted benzaldehyde derivative and preparation method thereof | 上海罕道医药科技有限公司 | 2021-08-24 | — | — | CN | claimed |
| EP-4727591-A1 | SMARCA2 DEGRADERS AND USES THEREOF | Astrazeneca AB (SE) | 2026-04-22 | — | — | EP | disclosed |
| US-12534453-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-12503468-B2 | Heterocyclic compound, intermediate, preparation method therefor and application thereof | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2025-12-23 | — | — | US | disclosed |
| EP-4662208-A1 | COMPOUNDS AND COMPOSITIONS FOR SELECTIVE DEGRADATION OF ENGINEERED PROTEINS | Celgene Corporation (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250215012-A1 | IKZF2 DEGRADERS AND USES THEREOF | UNIV MICHIGAN (US) | 2025-07-03 | — | — | US | disclosed |
| CN-119731179-A | IKZF2 degradation agent and application thereof | 密歇根大学董事会 | 2025-03-28 | — | — | CN | disclosed |
| EP-4499649-A1 | IKZF2 DEGRADERS AND USES THEREOF | Regents of the University of Michigan (US) | 2025-02-05 | — | — | EP | disclosed |
| WO-2024256988-A1 | SMARCA2 DEGRADERS AND USES THEREOF | ASTRAZENECA AB (SE) | 2024-12-19 | — | — | WO | disclosed |
| CN-119039290-A | P2X3 modulators | 葛兰素史密斯克莱知识产权(第3号)有限公司 | 2024-11-29 | — | — | CN | disclosed |
| US-20160376283-A1 | TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-12-29 | — | — | US | disclosed |
| CN-103130649-B | Liquid crystal compound and liquid crystal display | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (CN) | 2014-10-22 | — | — | CN | disclosed |
| US-8722156-B2 | Liquid crystal compound and liquid crystal display | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2014-05-13 | — | — | US | disclosed |
| US-20130235320-A1 | LIQUID CRYSTAL COMPOUND AND LIQUID CRYSTAL DISPLAY | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2013-09-12 | — | — | US | disclosed |
| CN-103130649-A | Liquid crystal compound and liquid crystal display | IND TECH RES INST | 2013-06-05 | — | — | CN | disclosed |
| US-7544400-B2 | Bimesogenic compounds and flexoelectric devices | MERCK PATENT GMBH (DE) | 2009-06-09 | — | — | US | disclosed |
| US-20080142758-A1 | Bimesogenic Compounds And Flexoelectric Devices | MERCK PATENT GMBH (DE) | 2008-06-19 | — | — | US | disclosed |
| EP-1828345-B1 | BIMESOGENIC COMPOUNDS AND FLEXOELECTRIC DEVICES | MERCK PATENT GMBH (DE) | 2008-05-14 | — | — | EP | disclosed |
| EP-1828345-A1 | BIMESOGENIC COMPOUNDS AND FLEXOELECTRIC DEVICES | Merck Patent GmbH (DE) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006066688-A1 | BIMESOGENIC COMPOUNDS AND FLEXOELECTRIC DEVICES | MERCK PATENT GMBH (DE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215012-A1 | IKZF2 DEGRADERS AND USES THEREOF | IKZF1, IKZF2, IKZF3 | TTR 1914/4885LMNA 2571/4885CA12 3905/4885 |
| US-20080142758-A1 | Bimesogenic Compounds And Flexoelectric Devices | MLX, FOXM1, SFXN1 | TTR 3275/4885LMNA 2202/4885CA12 1075/4885 |
| US-12534453-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | GYS1, GYS2, GBA1 | TTR 2413/4885LMNA 259/4885CA12 4149/4885 |
| US-12503468-B2 | Heterocyclic compound, intermediate, preparation method therefor and application thereof | P2RX3, P2RX7, P2RX4 | TTR 3580/4885LMNA 2553/4885CA12 2590/4885 |
| US-20160376283-A1 | TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF | NFKBIA, TBKBP1, TBK1 | TTR 2720/4885LMNA 2057/4885CA12 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.